Live Status Check

NCT07221149 Recruiting Status

Real-time enrollment status for this untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma clinical trial

Current Status

Recruiting

Auto-verified from ClinicalTrials.gov

Checked: July 13, 2026 at 7:51 AM UTC

NCT07221149 Status Summary

NCT NumberNCT07221149
Recruiting StatusRecruiting
ConditionUntreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
PhaseClinical Trial
Target Enrollment690 participants
Active Locations34 sites in the US
SponsorBristol-Myers Squibb
Last Updated on CT.govJune 26, 2026 (2 weeks ago)

About NCT07221149 Enrollment Status

As of July 13, 2026: Clinical trial NCT07221149 is currently recruiting participants. This clinical trial study for untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma is actively seeking new participants at 34 locations across the United States. The study is sponsored by Bristol-Myers Squibb. This status information is automatically verified from the official ClinicalTrials.gov registry.

Frequently Asked Questions About NCT07221149

Is NCT07221149 still recruiting?

Yes, NCT07221149 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.

Where is NCT07221149 recruiting?

This trial is recruiting at 34 locations in the United States. View all available locations on the full study page.

How do I enroll in NCT07221149?

Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.

When was NCT07221149 status last updated?

The official ClinicalTrials.gov record for NCT07221149 was last updated 2 weeks ago (June 26, 2026). HelloStudys verifies this status automatically.

Browse More Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Trials

Ready to Apply?

Check your eligibility for this clinical trial